Attached files
file | filename |
---|---|
EX-99.2 - JPM SLIDE DECK - Emergent BioSolutions Inc. | exhibit99_2.htm |
EX-99.1 - Emergent BioSolutions Inc. | exhibit99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 7, 2019
EMERGENT BIOSOLUTIONS INC.
(Exact name of registrant as specified in its charter)
DELAWARE
|
001-33137
|
14-1902018
|
||
(State or other jurisdiction
|
(Commission File Number)
|
(IRS Employer
|
||
of incorporation)
|
Identification No.)
|
400 Professional Drive, Suite 400,
Gaithersburg, Maryland 20879
(Address of principal executive
offices, including zip code)
(240) 631-3200
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
Item 7.01 Regulation FD Disclosure.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
|
Description
|
|
99.1
|
Press release, issued January 7, 2019.
|
|
99.2
|
Corporate slide deck, dated January 8, 2019.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
EMERGENT BIOSOLUTIONS INC.
|
||
|
|
|
Dated: January 7, 2019
|
By:
|
/s/ RICHARD S. LINDAHL
|
Name: Richard S. Lindahl
Title: Executive Vice
President, Chief Financial Officer and Treasurer
|
||
EXHIBIT INDEX
Description
|
||
Press release, dated January 7, 2019.
|
||
Corporate slide deck, dated January 8, 2019.
|